Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: GENFIT

Market Cap 50Cr 0 57Cr 46Cr 43Cr 81Cr 5.39TCr 81Cr 546.13Cr 212.09Cr 2.65TCr 214.52Cr 209.92Cr 9.2TCr P/E 2025
-3.06x
P/E 2026 * 52.6x
Enterprise Value 44Cr 0 51Cr 41Cr 38Cr 72Cr 4.79TCr 72Cr 486.11Cr 188.79Cr 2.36TCr 190.94Cr 186.85Cr 8.19TCr EV / Sales 2025
2.34x
EV / Sales 2026 * 4.74x
Free-Float
86.88%
Yield 2025 *
-
Yield 2026 * -
Manager TitleAgeSince
Chief Executive Officer 58 16/09/2019
Director of Finance/CFO 52 22/04/2021
Chief Tech/Sci/R&D Officer - 27/11/2025
Director TitleAgeSince
Chairman 70 16/06/2017
Director/Board Member 54 15/09/1999
Director/Board Member 58 16/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.34%-0.08%-12.15%-10.46% 4.34TCr
+2.53%+7.60%+302.13%+525.27% 3.35TCr
-2.46%-8.19%+7.52%-22.66% 2.85TCr
+2.99%+3.44%+6.51%+40.54% 2.92TCr
-0.57%+3.77%+12.66%+20.42% 2.53TCr
-0.34%+7.72% - - 1.44TCr
-0.18%-3.78%+51.01%+102.90% 1.31TCr
+0.54%-2.27%+3.93%+4.80% 1.27TCr
+0.48%+0.97%+101.39%+81.48% 1.23TCr
Average +0.29%+0.80%+59.12%+92.79% 2.36TCr
Weighted average by Cap. +0.36%+0.79%+62.08%+104.16%

Financials

2025 2026 *
Net sales 6.68Cr 0 7.67Cr 6.16Cr 5.79Cr 11Cr 722.73Cr 11Cr 73Cr 28Cr 356.17Cr 29Cr 28Cr 1.23TCr 9.52Cr 0 11Cr 8.78Cr 8.25Cr 15Cr 1.03TCr 16Cr 104.41Cr 41Cr 507.45Cr 41Cr 40Cr 1.76TCr
Net income -83.02L -0 -95.29L -76.53L -71.99L -1.35Cr -90Cr -1.36Cr -9.11Cr -3.54Cr -44Cr -3.58Cr -3.5Cr -153.39Cr 1.83Cr 0 2.1Cr 1.69Cr 1.59Cr 2.97Cr 198.01Cr 2.99Cr 20Cr 7.8Cr 98Cr 7.89Cr 7.72Cr 338.22Cr
Net Debt -5.47Cr -0 -6.28Cr -5.04Cr -4.74Cr -8.88Cr -591.89Cr -8.94Cr -60Cr -23Cr -291.69Cr -24Cr -23Cr -1.01TCr -4.69Cr -0 -5.38Cr -4.32Cr -4.06Cr -7.6Cr -506.95Cr -7.66Cr -51Cr -20Cr -249.83Cr -20Cr -20Cr -865.92Cr
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!